Video content above is prompted by the following questions:
How has the story of CLL treatment evolved in recent history? What are the latest trends and innovations you have observed in the treatment and management of CLL leading up to ASCO 2024?
Coming into ASCO 2024, what would you consider to be the largest unmet needs in the treatment and management of CLL?
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.